We are live on ! Find out more
HEPA

Hepion Pharmaceuticals
HEPA

Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

4 hedge funds and large institutions have $901K invested in Hepion Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

31% less capital invested

Capital invested by funds: $1.3M → $901K (-$400K)

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$31K
2
PAG
Private Advisor Group
New Jersey
-$14K
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$12K
4
Bank of New York Mellon
Bank of New York Mellon
New York
-$9K
5
TSS
Two Sigma Securities
New York
-$8K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$416K – – –
HighTower Advisors
2
HighTower Advisors
Illinois
$169K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$81K – – –
Barclays
4
Barclays
United Kingdom
$67K – – –
CS
5
Credit Suisse
Switzerland
$41K – – –
Morgan Stanley
6
Morgan Stanley
New York
$34K – – –
JP Morgan Chase
7
JP Morgan Chase
New York
$33K – – –
Northern Trust
8
Northern Trust
Illinois
$26K – – –
PFS
9
Prospera Financial Services
Texas
$26K – – –
BlackRock
10
BlackRock
New York
$8K – – –
Bank of Montreal
11
Bank of Montreal
Ontario, Canada
– -$12K – –
Bank of New York Mellon
12
Bank of New York Mellon
New York
– -$9K – –
Citadel Advisors
13
Citadel Advisors
Florida
– -$31K – –
IWM
14
IHT Wealth Management
Illinois
– -$1K – –
LPL Financial
15
LPL Financial
California
– -$4K – –
PAG
16
Private Advisor Group
New Jersey
– -$14K – –
RJFSA
17
Raymond James Financial Services Advisors
Florida
– -$4K – –
TSS
18
Two Sigma Securities
New York
– -$8K – –
USAA
19
United Services Automobile Association
Texas
– -$4K – –
VF
20
Virtu Financial
New York
– -$2K – –

HEPA Hedge Fund Activity: Q2 2018 in Review

4 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q2 2018, worth a combined $901K — down 31% from $1.3M a quarter earlier.

Fund positioning in HEPA was balanced in Q2 2018: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

The largest seller was Citadel Advisors, cutting an estimated $31K.

  • 4 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q2 2018, unchanged from Q1 2018.
  • Funds reported $901K of Hepion Pharmaceuticals stock for Q2 2018, down 31% quarter-over-quarter.
  • 0 funds opened new Hepion Pharmaceuticals positions in Q2 2018 and 0 closed out.
  • The largest Hepion Pharmaceuticals seller in Q2 2018 was Citadel Advisors, an estimated $31K sold.

Based on aggregated 13F filings for Q2 2018.